Mandate

Vinge advises Vicore Pharma in connection with its listing on Nasdaq Stockholm

September 23, 2019 Capital Markets and Public M&A

Vinge advises Vicore Pharma Holding AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market.

The prospectus was published on 16 September 2019 and the trading on Nasdaq Stockholm will commence on 27 September 2019.

Vicore Pharma is a Swedish rare disease pharmaceutical company focused on interstitial lung diseases and related indications. The company currently has two drug development programs in preclinical or clinical phase.

Vinge’s team has primarily consisted of Jesper Schönbeck, Nils Fredrik Dehlin, Astrid Isberg, Emelie Svanberg, Viktor Bergsten and Sofia Bergenstråhle.

Related

Vinge advises ABG Sundal Collier in connection with Conapto's issue of subsequent senior secured bonds of SEK 500 million

Vinge has advised ABG Sundal Collier as arranger in connection with Conapto Holding AB (publ)'s issue of subsequent senior secured bonds of SEK 500 million under the existing framework of SEK 2 billion.
April 24, 2026

Vinge advises GBL on its acquisition of BUKO Group

Vinge, together with Latham & Watkins, advises Groupe Bruxelles Lambert (“GBL”) (Euronext Brussels: GBLB) on its acquisition of BUKO Group, a leading platform in temporary traffic management, from funds advised by Equistone Partners Europe and the founding family, while management will re-invest alongside GBL. The transaction, which is subject to customary approvals, will entail a EUR 0.5 billion equity investment by GBL.
April 24, 2026

Vinge advise Lagercrantz Group on the business acquisition of FMK Trafikprodukter

Lagercrantz Group, through its subsidiary Nordic Road Safety, has entered into an agreement to acquire the business and assets of FMK Trafikprodukter – a niche company specialising in CE-certified road barrier systems for the Swedish and Nordic infrastructure market.
April 24, 2026